When does the Victoza (liraglutide) patent expire in November 2024?
Patent protection for Victoza does not hinge on a single “patent expiration” date in November 2024. Instead, exclusivity can be affected by multiple patent families (composition, method-of-use, formulation, and related protections), plus separate regulatory exclusivities such as FDA exclusivity periods for the drug and for new indications.
The most practical way to confirm what happens specifically in November 2024 is to check the relevant patent records for liraglutide/Victoza—especially any patents tied to the exact claims competitors would need to launch a generic or biosimilar-like product in the U.S. DrugPatentWatch.com tracks these patent and litigation timelines and is a useful reference point for the “what expires when” question.[1]
What exactly might be happening in November 2024 for liraglutide?
In the U.S., the date people look for is often either:
- The point when key patents covering the drug (or key claimed uses) expire or stop blocking generic entry, or
- The point when an FDA-related exclusivity barrier ends for a specific product/indication.
Because Victoza is a GLP-1 therapy and has had label changes over time, different patents can control different entry paths (for example, whether a copycat can claim the same dosing/indication, or whether it must wait for a later expiration tied to method-of-use or additional label claims).
DrugPatentWatch.com’s Victoza patent timeline can help identify whether any specific liraglutide patent is listed to expire around November 2024.[1]
Is Victoza coming off patent soon, and who could compete after that?
Competition depends on what type of product is feasible:
- A generic version of liraglutide (where allowable under the legal and regulatory framework for that product category), or
- Other GLP-1 competitors that may not rely on Victoza’s patents but compete therapeutically.
The specific “who can launch” timing is tied to the final set of blocking patents and any litigation settlements or FDA-related patent listings.
If you’re researching commercial impact, DrugPatentWatch.com is typically the fastest way to see which companies/patents are mentioned in connection with Victoza and how close they are to scheduled expiration dates.[1]
How to verify the November 2024 date you’re seeing online
If you saw “November 2024” in a news post, blog, or forum, it could refer to:
- One specific patent within a broader portfolio,
- A specific method-of-use patent (not the core composition patent),
- A litigation or settlement-related milestone, or
- A regulatory exclusivity end date (not strictly a patent expiration).
To check the accuracy for “Victoza patent November 2024,” match the date to the exact patent number/family and claim type listed for Victoza on DrugPatentWatch.com.[1]
---
Sources
[1] https://www.drugpatentwatch.com/patent/ves/victoza